As previously reported, Benchmark upgraded Emergent BioSolutions to Buy from Hold with a $5 price target after the company reported “upbeat financial results” for Q4. The company also provided financial guidance for 2024, during the earnings call introduced new CEO Joseph Papa and announced a new forbearance agreement with its primary lenders through April 30, notes the analyst, who sees the company continuing its turnaround.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EBS:
- Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
- Emergent BioSolutions Secures Flexible Credit Terms and Guarantor
- Emergent BioSolutions options imply 25.1% move in share price post-earnings
- Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
- Biotech Alert: Searches spiking for these stocks today